EP1032420A4 - Immunoglobulin molecules having a synthetic variable region and modified specificity - Google Patents

Immunoglobulin molecules having a synthetic variable region and modified specificity

Info

Publication number
EP1032420A4
EP1032420A4 EP98958583A EP98958583A EP1032420A4 EP 1032420 A4 EP1032420 A4 EP 1032420A4 EP 98958583 A EP98958583 A EP 98958583A EP 98958583 A EP98958583 A EP 98958583A EP 1032420 A4 EP1032420 A4 EP 1032420A4
Authority
EP
European Patent Office
Prior art keywords
variable region
immunoglobulin molecules
synthetic variable
modified specificity
specificity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98958583A
Other languages
German (de)
French (fr)
Other versions
EP1032420A1 (en
Inventor
Ronald M Burch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of EP1032420A1 publication Critical patent/EP1032420A1/en
Publication of EP1032420A4 publication Critical patent/EP1032420A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
EP98958583A 1997-11-14 1998-11-13 Immunoglobulin molecules having a synthetic variable region and modified specificity Withdrawn EP1032420A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6571697P 1997-11-14 1997-11-14
US65716P 1997-11-14
US8140398P 1998-04-10 1998-04-10
US81403P 1998-04-10
PCT/US1998/024302 WO1999025378A1 (en) 1997-11-14 1998-11-13 Immunoglobulin molecules having a synthetic variable region and modified specificity

Publications (2)

Publication Number Publication Date
EP1032420A1 EP1032420A1 (en) 2000-09-06
EP1032420A4 true EP1032420A4 (en) 2004-09-15

Family

ID=26745908

Family Applications (2)

Application Number Title Priority Date Filing Date
EP98958584A Withdrawn EP1030684A4 (en) 1997-11-14 1998-11-13 Modified antibodies with enhanced ability to elicit an anti-idiotype response
EP98958583A Withdrawn EP1032420A4 (en) 1997-11-14 1998-11-13 Immunoglobulin molecules having a synthetic variable region and modified specificity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP98958584A Withdrawn EP1030684A4 (en) 1997-11-14 1998-11-13 Modified antibodies with enhanced ability to elicit an anti-idiotype response

Country Status (9)

Country Link
EP (2) EP1030684A4 (en)
JP (2) JP2002507544A (en)
KR (2) KR20010015817A (en)
CN (2) CN1327388A (en)
AU (2) AU763029B2 (en)
BR (2) BR9815289A (en)
CA (2) CA2310269A1 (en)
IL (2) IL136114A0 (en)
WO (2) WO1999025379A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2350917A1 (en) * 1998-11-13 2000-05-25 Euro-Celtique, S.A. Contraceptive antibody vaccines
DK1092779T3 (en) * 1999-10-11 2010-02-15 Pasteur Institut Lentivirus virus vectors for the preparation of immunotherapeutic preparations
AU2001261628A1 (en) * 2000-05-16 2001-11-26 Euroceltique S.A. Cd28 synthebody for the modulation of immune responses
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
EP1498429A3 (en) * 2000-12-05 2005-08-03 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
WO2002078613A2 (en) * 2001-04-02 2002-10-10 Purdue Pharma L.P. Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response
WO2003063768A2 (en) * 2001-10-25 2003-08-07 Euro-Celtique S.A. Compositions and methods directed to anthrax toxin
ES2301794T3 (en) * 2002-04-09 2008-07-01 The Curators Of The University Of Missouri TREATMENT OF TYPE 1 DIABETES, BEFORE AND AFTER THE EXPRESSION OF PREDISPOSITION MARKERS.
NZ536475A (en) 2002-05-24 2008-06-30 Schering Corp Neutralizing human anti-igfr antibody
AR040778A1 (en) * 2002-08-06 2005-04-20 Glaxo Group Ltd ALTERED ANTIBODIES OR FUNCTIONAL FRAGMENTS THAT BIND MAG (GLICOPROTEIN ASSOCIATED WITH HONEY).
NZ538996A (en) 2002-10-31 2008-04-30 Genentech Inc Methods and compositions for increasing antibody production
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
WO2005021595A1 (en) * 2003-08-28 2005-03-10 Euro-Celtique S.A. Methods of antibody engineering using antibody display rules
EP1694850B1 (en) 2003-11-12 2011-06-29 Schering Corporation Plasmid system for multigene expression
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
CA2558813A1 (en) * 2004-03-09 2005-09-15 Kyoto University Pharmaceutical composition comprising cxcr3 inhibitor
ATE493442T1 (en) 2004-12-03 2011-01-15 Schering Corp BIOLOGICAL MARKERS FOR PRE-SELECTION OF PATIENTS FOR ANTI-IGF1R THERAPY
ZA200901165B (en) * 2006-08-28 2010-06-30 Kyowa Hakko Kirin Co Ltd Antagonistic human light-specific human monoclonal antibodies
GB0706070D0 (en) 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
NZ587305A (en) * 2008-03-12 2012-05-25 Imclone Llc Anti-tyrosinase-realted protein-1 (TYRP1) antibodies
JP5925116B2 (en) * 2009-04-29 2016-05-25 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド ERG monoclonal antibody
CN102816240B (en) * 2011-03-08 2014-02-12 中国人民解放军第三军医大学第二附属医院 Fusion protein and fusion protein expression vector thereof
WO2012166712A1 (en) * 2011-05-27 2012-12-06 Fox Chase Cancer Center Rationally-designed anti-mullerian inhibiting substance type ii receptor antibodies
US9902760B2 (en) * 2011-11-23 2018-02-27 Bioven 3 Limited Recombinant proteins and their therapeutic uses
JP5437525B1 (en) 2012-12-28 2014-03-12 株式会社ナード研究所 Tyrosine derivative and method for producing tyrosine derivative
CN105705522B (en) * 2013-05-14 2020-09-15 上海亨臻实业有限公司 Epitope vaccine aiming at low-immunogenicity protein and preparation method and application thereof
CN103275914B (en) * 2013-06-03 2015-04-01 中国人民解放军军事医学科学院微生物流行病研究所 Bacterial ghost presenting protective antigens and application thereof
CN105263953B (en) * 2014-01-15 2020-01-07 勃林格殷格翰动物保健美国有限公司 Porcine parvovirus 5A, methods of use, and vaccines
JP6705755B2 (en) * 2014-05-19 2020-06-03 バロ セラピューティクス オイＶａｌｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｏｙ Modified adenovirus for cancer vaccine development
CN105693859B (en) * 2016-03-22 2019-06-21 苏州莱泰生物科技有限公司 Anti-human G2A monoclonal antibody and the kit for detecting human macrophage G2A expression quantity
CN111978382B (en) * 2020-09-03 2022-03-04 吉林大学第一医院 Preparation method and application of recombinant protein of Sporothrix globosum Gp70
CN112646029B (en) * 2020-12-30 2022-07-29 深圳清华大学研究院 Antibody of mature brain-derived neurotrophic factor, application thereof and diagnostic kit
CN115856296B (en) * 2022-12-16 2023-07-25 华北理工大学 Monoclonal antibody for resisting shigella and application thereof in detection

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004380A1 (en) * 1990-09-07 1992-03-19 Unilever Plc Specific binding agents
WO1992011383A1 (en) * 1990-12-21 1992-07-09 Celltech Limited RECOMBINANT ANTIBODIES SPECIFIC FOR TNF$g(a)
WO1994010323A1 (en) * 1992-11-04 1994-05-11 Imperial Cancer Research Technology Limited Virus with modified binding moiety specific for the target cells
WO1994014847A1 (en) * 1992-12-24 1994-07-07 The Regents Of The University Of California Genetically engineered immunoglobulins
WO1994014848A1 (en) * 1992-12-24 1994-07-07 The Regents Of The University Of California Genetically engineered immunoglobulins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688657A (en) * 1988-03-31 1997-11-18 International Bio-Immune Systems, Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
EP0460076B1 (en) * 1989-02-24 1995-11-29 The Regents Of The University Of California Genetically engineered immunoglobulins
AU6396494A (en) * 1992-11-16 1994-06-08 Cancer Research Fund Of Contra Costa Peptides and anti-sense peptides with broad neoplastic specificity
US5476784A (en) * 1993-04-06 1995-12-19 Rice; Peter A. Gonococcal anti-idiotypic antibodies and methods and compositions using them
US5653977A (en) * 1993-09-09 1997-08-05 Uab Research Foundation Anti-idiotypic antibody that mimics the GD2 antigen
US5624904A (en) * 1993-11-17 1997-04-29 Massachusetts Institute Of Technology Method for treating gram positive septicemia

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004380A1 (en) * 1990-09-07 1992-03-19 Unilever Plc Specific binding agents
WO1992011383A1 (en) * 1990-12-21 1992-07-09 Celltech Limited RECOMBINANT ANTIBODIES SPECIFIC FOR TNF$g(a)
WO1994010323A1 (en) * 1992-11-04 1994-05-11 Imperial Cancer Research Technology Limited Virus with modified binding moiety specific for the target cells
WO1994014847A1 (en) * 1992-12-24 1994-07-07 The Regents Of The University Of California Genetically engineered immunoglobulins
WO1994014848A1 (en) * 1992-12-24 1994-07-07 The Regents Of The University Of California Genetically engineered immunoglobulins

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 10, no. 2, 2000, pages 251 - 253, XP002288085 *
LANZA P ET AL: "ACTIVE IMMUNITY AGAINST THE CDH RECEPTOR BY USING AN ANTIBODY ANTIGENIZED WITH RESIDUES 41-55 OF THE FIRST EXTRACELLULAR DOMAIN", 1 December 1993, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, PAGE(S) 11683-11687, ISSN: 0027-8424, XP000578386 *
LANZA P ET AL: "SELECTIVE INTERACTION OF A CONFORMATIONALLY-CONSTRAINED ARG-GLY-ASP (RGD) MOTIF WITH THE INTEGRIN RECEPTOR ALPHAVBETA3 EXPRESSED ON HUMAN TUMOR CELLS", BLOOD CELLS, MOLECULES AND DISEASES, LAJOLLA, US, vol. 23, no. 12, 30 June 1997 (1997-06-30), pages 230 - 241, XP001193348, ISSN: 1079-9796 *
RIGAUDY P ET AL: "ANTIBODIES SPECIFIC FOR THE NEURONAL FORM OF THE SRC PROTEIN ELICITED BY AN ANTIGENIZED ANTIBODY", 1994, DNA, MARY ANN LIEBERT, NEW YORK, NY, US, PAGE(S) 585-591, ISSN: 1044-5498, XP008032317 *
See also references of WO9925378A1 *
SHARMA J N: "THERAPEUTIC PROSPECTS OF BRADYKININ RECEPTOR ANTAGONISTS", 1993, GENERAL PHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, PAGE(S) 267-274, ISSN: 0306-3623, XP000563698 *
ZANETTI M ET AL: "THEORETICAL AND PRACTICAL ASPECTS OF ANTIGENIZED ANTIBODIES", IMMUNOLOGICAL REVIEWS, MUNKSGAARD, XX, no. 130, December 1992 (1992-12-01), pages 125 - 150, XP008032319, ISSN: 0105-2896 *

Also Published As

Publication number Publication date
EP1032420A1 (en) 2000-09-06
IL136114A0 (en) 2001-05-20
AU1459899A (en) 1999-06-07
AU737457B2 (en) 2001-08-23
BR9815289A (en) 2001-12-26
JP2001526021A (en) 2001-12-18
WO1999025379A1 (en) 1999-05-27
WO1999025378A9 (en) 1999-08-12
AU1459799A (en) 1999-06-07
CN1294517A (en) 2001-05-09
BR9815580A (en) 2002-01-29
CA2310269A1 (en) 1999-05-27
IL136113A0 (en) 2001-05-20
EP1030684A1 (en) 2000-08-30
AU2003252902A1 (en) 2003-11-06
AU763029B2 (en) 2003-07-10
EP1030684A4 (en) 2004-09-15
JP2002507544A (en) 2002-03-12
WO1999025378A1 (en) 1999-05-27
KR20010015818A (en) 2001-02-26
CA2309990A1 (en) 1999-05-27
KR20010015817A (en) 2001-02-26
CN1327388A (en) 2001-12-19

Similar Documents

Publication Publication Date Title
IL136114A0 (en) Immunoglobulin molecules having a synthetic variable region and modified specificity
GB2338952B (en) Synthetic closure
GB9810246D0 (en) Clip friction hinge
ZA95260B (en) Synthetic receptors libraries and uses thereof
IL113343A0 (en) CTLA4 molecules and their uses
ZA962768B (en) Benzonitriles and benzofluorides
SG79882A1 (en) Protein having tpo activity
EP0856030A4 (en) Lignin-based friction material
GB9721961D0 (en) Novel molecules
GB2290577B (en) Concealed fixing clip
EP0817817A4 (en) Novel ice-controlling molecules and their applications
GB9613198D0 (en) Clip type fastener
EP0695882A3 (en) Fastening element
EP0772658A4 (en) Friction material
GB9625158D0 (en) Clips
ZA9949B (en) Immunoglobulin molecules having a synthetic variable region and modified specificity.
AU3000997A (en) Mild synthetic detergent base material and mild synthetic detergent bar produced therefrom
HK1003896A1 (en) Protein having tpo activity
GB9512124D0 (en) Ammoxidation of propane
GB9606327D0 (en) Methacrylated or acrylated cyanoacetates and the adhesives and polymers thereof
ZA951199B (en) Protein having tpo activity
GB9515850D0 (en) Broad specificity antibodies
GB9515407D0 (en) Synthetic interlinking of molecules
GB9415488D0 (en) Synthetic interlinking of molecules
SG77159A1 (en) Novel anti-clotting molecules and uses therefor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000609

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20040803

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060601

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1031995

Country of ref document: HK